Google Alert - finance

	finance As-it-happens update ⋅ August 9, 2022
	NEWS
	Cancer Network Frontline Tremelimumab/Durvalumab Combo Shows Promising Survival Benefit in Hard-to-Treat Subgroups of mNSCLC Cancer Network Patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations experienced a survival benefit following treatment with tremelimumab plus durvalumab and chemotherapy in the first line. Flag as irrelevant
See more results | Edit this alert

You have received this email because you have subscribed to Google Alerts. Unsubscribe | View all your alerts

Receive this alert as RSS feed

Send Feedback